本公告乃藥師幫股份有限公司（「本公司」）自 願 刊 發，以 告 知 其 股 東 及 潛 在 投 資 者有關本公司連同其附屬公司及綜合聯屬實體（「本集團」）若干業務發展最新 情 況。除 另 有 界 定 者 外，本 公 告 所 用 詞 彙 與 本 公 司 於2025年4月25日刊發的年度 報 告（「年 報」）所 界 定 者 具 相 同 涵 義。 茲提述本公司日期為2025年5月14日 有 關 業 務 發 展 最 新 情 況 的 自 願 性 公 告。廠 牌首推業務乃本集團「向 上 走」方 案 中 的 一 項 重 要 戰 略，同 時 作 為 高 利 潤 業 務， 因 此 對 提 升 盈 利 能 力 而 言 舉 足 輕 重。誠 如 年 報 所 披 露，根 據 本 公 司 自 其 他 業 務 運 營 所 獲 得 的 洞 察，本 公 司 積 極 尋 求 與 藥 企 建 立 深 度 合 作，旨 在 協 助 它 們 將 針 對 下 游 需 求 定 制 的 產 品 推 向 更 廣 闊 的 市 場，從 而 將 潛 在 的 市 場 機 遇 轉 化 為 實 實 在 在 的 銷 售 業 績。另 一 方 面，依 託 本 公 司 已 經 構 ...

Core Viewpoint - The company emphasizes the importance of external collaboration to expand market boundaries and enhance customer loyalty while increasing business value [1] Group 1 - The company is committed to strengthening corporate cooperation and collaboration to enhance regional advantages [1] - The company will strictly adhere to information disclosure regulations for significant external cooperation matters [1] - The company aims to improve business development through enhanced internal management, improved business processes, optimized business structure, and expanded business models [1] Group 2 - The company focuses on continuous quality improvement and efficiency enhancement to ensure sustainable, healthy, and stable development [1]

Core Viewpoint - The company held an online investor meeting to discuss its strategic planning and business development, focusing on high-quality growth in automotive and aerospace components, as well as new areas like hot-formed components and drone manufacturing [1]. Group 1: Strategic Planning - The company aims to adhere to a strategy of "strategic leadership, innovation-driven, and collaborative development" [1]. - The focus will be on high-quality development in automotive components, aerospace components, and tooling business [1]. - The company is also seeking breakthroughs in new fields such as hot-formed components [1]. Group 2: Drone Business - Drone body manufacturing is identified as an important new direction for the company [1]. - This initiative has been included in the "14th Five-Year Plan" and is currently in the exploratory cultivation phase [1]. - The timeline for industrialization of the drone business remains uncertain [1]. Group 3: Business Focus - In addition to automotive molds, the company plans to leverage new technology research and applications to prioritize the development of automotive and aerospace components [1].

Core Viewpoint - Haomai Technology held an investor relations event, revealing strong financial performance in the first half of 2025, with significant revenue growth across various business segments [1] Financial Performance - In the first half of 2025, Haomai Technology achieved revenue of 5.265 billion yuan, a year-on-year increase of 27.25% [1] - The net profit attributable to shareholders was 1.197 billion yuan, reflecting a year-on-year growth of 24.65% [1] - Tire mold revenue reached 2.628 billion yuan, up 18.56%, with a gross margin of 40.21%, down 1 percentage point year-on-year [1] - Large component machinery products generated revenue of 1.947 billion yuan, a 32.94% increase, with a gross margin of 24.30%, up 0.22 percentage points [1] - CNC machine tool revenue surged to 506 million yuan, marking a 145.08% increase [1] Business Segment Insights - Tire mold business gross margin decline attributed to changes in product structure and an increase of over 1,000 personnel [1] - Large component machinery products benefited from strong demand in the gas turbine and wind power markets, with full production line operations [1] - The gas turbine components account for approximately 30% and wind power components for about 60% of large component machinery products [1] - CNC machine tool business has seen repeat orders and increased procurement from diverse industries since its market launch in 2022 [1] Construction and Expansion - Ongoing construction projects include expansions in casting, machine tools, and mold businesses, with a 65,000-ton casting expansion project coming online [1] - The machine tool facility's main structure is nearing completion, expected to be ready for assembly by year-end [1] - Sulfur machine business revenue was approximately 110 million yuan, with anticipated growth in the second half of the year despite initial order delays [1] Cost Structure - In 2024, raw material costs accounted for about one-third of tire mold business costs and around 50% for large component machinery products [1] - Key raw materials for tire molds include forged steel and aluminum ingots, while large component machinery relies on pig iron and scrap steel [1]

Group 1 - The company reported a negative cash flow of 911 million yuan for the first half of the year, primarily due to increased procurement payments and the timing of project execution, which affected the collection of receivables [2] - The company expects to gradually receive related payments as projects progress and settle [2] - Currently, the company has sufficient bank credit reserves and a solid financial turnover capability to support business development, with no plans for refinancing or restructuring mergers and acquisitions [2]

Core Viewpoint - Aidi Kang Holdings (09860) reported a mid-term performance for the six months ending June 30, 2025, with revenue of RMB 1.271 billion, a year-on-year decrease of 13.31% [1] Financial Performance - The company's total revenue reached RMB 1.271 billion, reflecting a decline of 13.3% year-on-year [1] - Profit attributable to equity holders of the parent company was RMB 27.273 million, down 73.15% year-on-year [1] - Earnings per share stood at RMB 0.04 [1] Business Segments - The co-construction business revenue grew by 30% year-on-year, with a four-year compound annual growth rate (CAGR) of 48%, primarily driven by successful projects with major tertiary hospitals [1] - The CRO (Contract Research Organization) business revenue increased by 18% year-on-year, supported by deep collaborations with leading domestic and international pharmaceutical companies [1] - The company maintained a strong position in the diabetes sector, achieved robust performance in the NASH (Non-Alcoholic Steatohepatitis) field, and made innovative breakthroughs in solid tumor treatment, expanding its business landscape [1] Future Outlook - The company plans to deepen strategic cooperation with leading medical institutions in the second half of the year to promote more benchmark projects [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Zhong Jia Guo Xin Holdings Company Limited 中加國信控股股份有限公司 （於百慕達註冊成立之有限公司） （股份代號：899） 自願性公告 業務最新情況 本公告乃由中加國信控股股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願公佈，旨在向本公司股東（「股東」）及潛在投資者提供本集團最新業務發展情況。 本公司董事（「董事」）會（「董事會」）謹此通知根據截至二零二五年三月三十一日止年 度的年度報告，集團曾於二零二四年四月一日作出預測（「預測」），預期截至二零二五年 三月三十一日止年度將實現租金收入約1027萬港元及礦產銷售約1302萬港元。而實際該年度 租金收入約755萬港元，礦產銷售為0港元，較預測值分別出現約29.57%（「租金差額」）及 100%（「礦產差額」）的差額（統稱「差額」）。 公司本預期，在新冠疫情限制措施解除後，中國經濟將在2024年有所好 ...

Summary of Pfizer's Conference Call Company Overview - **Company**: Pfizer Inc. - **Date**: August 6, 2025 Key Industry Insights - **Strategic Focus**: Pfizer's 2025 strategy emphasizes enhancing R&D productivity through workforce and process streamlining, leveraging technology and AI for operational optimization. The company anticipates cumulative cost savings of $7.7 billion by the end of 2027, aimed at improving business profitability [2][18][19]. Core Product Performance - **Eliquis**: Strong market performance, particularly in the UK and Spain, with significant growth noted. In initial treatment for third-line indications, the median overall survival exceeds 2 years, more than double historical figures [2][5]. - **Keytruda**: Demonstrated a total response rate exceeding 97% in newly diagnosed multiple myeloma patients when administered as a subcutaneous fixed-dose regimen, with controllable safety [2][5]. R&D Developments - **Non-Small Cell Lung Cancer**: Advancements in the development of a beta6abc integrin inhibitor, with a confirmed response rate of 31% in second-line populations and a 57% response rate in first-line treatment patients [2][6]. - **Hemophilia Treatment**: Introduction of a subcutaneous self-injector for hemophilia A or B, achieving a 93% reduction in annual bleeding rates, outperforming approved products [2][7][8]. - **Vaccine Candidates**: A second-generation vaccine candidate shows 100% efficacy against difficult infections, currently in Phase II trials, with plans for Phase III trials. A Lyme disease vaccine candidate is expected to submit for approval next year [2][9]. Financial Performance - **Q2 2025 Results**: Pfizer reported revenues of $14.7 billion, a 10% year-over-year increase. Adjusted diluted EPS was $0.78, exceeding expectations. The company maintains a full-year revenue outlook of $61 billion to $64 billion [3][4][17]. - **Cost Management**: Pfizer achieved an 8% reduction in adjusted operating expenses, with R&D expenses down 9%. The first phase of manufacturing optimization is expected to yield $1.5 billion in savings [18]. Market Position and Competitive Strategy - **BMS-Pfizer Alliance**: The alliance holds a 47% market share in the oral CDRP category, enhancing competitiveness through customized dosing options and expanded channels [4][12]. - **International Market Growth**: Strong performance in international markets, with a 32% increase in patient treatment volumes, and a 50% increase year-to-date [35][36]. Future Outlook - **Business Development**: Pfizer plans to pursue smaller-scale transactions to achieve a $1-1.5 billion capacity target, with a focus on oncology, vaccines, and internal medicine [21][28]. - **Regulatory Environment**: The company is actively engaging with U.S. government entities regarding competitive pressures from Chinese biotechnology firms and is preparing for potential impacts from proposed trade and tariff policies [29][30][37]. Additional Considerations - **Vaccine Uptake**: Changes in CDC vaccine recommendations may impact vaccination rates, but Pfizer anticipates a strong upcoming season due to robust supply and distribution capabilities [20]. - **Capital Allocation**: Pfizer's capital allocation strategy remains cautious, focusing on pipeline execution and operational efficiency [47]. This summary encapsulates the key points from Pfizer's conference call, highlighting the company's strategic initiatives, product performance, financial results, and future outlook in the pharmaceutical industry.

Group 1 - Company Liyuan Technology (SH 688565) announced the signing of two contracts with China Power Engineering Consulting Group Northwest Electric Power Design Institute, totaling RMB 31.494 million and RMB 15.37 million for chemical water treatment systems and boiler feed water treatment systems respectively [2] - The contracts are part of the EPC general contracting projects for a 2.64 million kilowatt new energy and coal power integrated carbon capture project and a 2×66 million kilowatt cogeneration project [2] - The contract guarantee period is two years from the completion acceptance date, which is expected to strengthen the company's leading position in the thermal power market and enhance its sustainable profitability and core competitiveness [2]

Fundraising Plan - The company plans to raise a total of 956,340,000.00 yuan through a private placement, with the net proceeds to be used entirely for debt repayment and to supplement working capital [1][2] Necessity and Feasibility Analysis - The necessity of the fundraising is highlighted by the company's significant debt, totaling approximately 1.512 billion yuan, with a high asset-liability ratio of 85.75% as of the end of 2024. The current cash balance of 118 million yuan is insufficient to cover these debts [1][2] - The feasibility of the fundraising is supported by its alignment with relevant policies and regulations, as well as the company's operational needs. The funds will help optimize the capital structure and enhance debt repayment capacity [2][3] Impact on Financial Status and Management - The fundraising is expected to positively impact the company's financial status by significantly increasing total assets and net assets, thereby improving the asset structure and reducing the asset-liability ratio [3][4] - The funds will alleviate debt pressure, enhance financial stability, and support ongoing business operations and product innovation, ultimately improving competitiveness and profitability [2][4] Governance and Fund Management - The company has established a governance structure in line with listing standards, ensuring independent operation of the board and management. A fundraising management system is in place to oversee the use of raised funds [3][4]